

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <http://orca.cf.ac.uk/96982/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Subramanian, Leena, Bracht, Tobias, Jenkins, P., Choppin, S., Linden, David Edmund Johannes, Phillips, G. and Simpson, B. A. 2016. Clinical improvements following bilateral anterior capsulotomy in treatment-resistant depression. *Psychological Medicine* 47 (6) , pp. 1097-1106. 10.1017/S0033291716003159 file

Publishers page: <https://doi.org/10.1017/S0033291716003159>
<<https://doi.org/10.1017/S0033291716003159>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



1 **Clinical improvements following bilateral anterior capsulotomy in treatment-resistant depression**

2 Leena Subramanian, PhD^{1,2}, Tobias Bracht, MD², Peter Jenkins, FRCPsych³, Sabine Choppin, MD⁴,

3 David E.J. Linden, MD^{1,2,5}, Gwen Phillips, DipClinPsych⁵, Brian A. Simpson, MD, FRCS⁵

4

5 1) MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological

6 Medicine & Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, UK

7 2) Cardiff University Brain Research Imaging Centre, School of Psychology, Cardiff University,

8 Cardiff, UK

9 3) Cyncoed Consulting Rooms, Cardiff, UK

10 4) Universite Pierre et Marie Curie, Paris, France

11 5) Cardiff and Vale University Health Board, Cardiff, UK

12

13 **Abstract:**

14 **Background:** The purpose of the present study was to evaluate a programme of lesion surgery

15 carried out on patients with treatment-resistant depression (TRD).

16 **Methods:** This was a retrospective study looking at clinical and psychometric data from 45 patients

17 with TRD who had undergone bilateral stereotactic anterior capsulotomy surgery over a period of 15

18 years, with the approval of the Mental Health Act Commission (MHAC), (37 with unipolar depression

19 and eight with bipolar disorder). The Beck Depression Inventory (BDI) before and after surgery was

20 used as the primary outcome measure. The Montgomery Asberg Depression Rating Scale (MADRS)

21 was administered and cognitive aspects of executive and memory functions were also examined. We

22 carried out a paired samples t-test on the outcome measures to determine any statistically

23 significant change in the group as a consequence of surgery.

24 **Results:** Patients improved on clinical measure of depression after surgery by -21.20 points on the

25 BDI with a 52% change. There were no significant cognitive changes post-surgery. Six patients were

26 followed up in 2013 by phone interview and reported a generally positive experience. No major
27 surgical complications occurred.

28 **Conclusions:** With the limitations of an uncontrolled, observational study, our data suggest that
29 capsulotomy can be an effective treatment for otherwise TRD. Performance on neuropsychological
30 tests did not deteriorate.

31

32 Keywords: (1) Anterior capsulotomy, (2) Depression, (3) Mood disorder, (4) Stereotactic
33 neurosurgery, (5) Treatment resistance

34

35 **INTRODUCTION:**

36 Current first line treatments for depression are antidepressant medication and psychotherapy, but
37 70% of patients do not respond to the first choice of treatment (Carvalho *et al.* 2014). Non-response
38 to two or more antidepressant regimes of adequate duration and dosage is considered to denote a
39 “treatment-refractory” depression (El-Hage *et al.* 2013). Several lines of pharmacological
40 augmentation are available, but even with optimal drug regime and augmentation 10-30% of
41 patients remain refractory (Rakofsky *et al.* 2009). Many of these patients will still get – at least
42 temporary – relief from electroconvulsive therapy (ECT) (UK ECT Review Group, 2003). However,
43 some patients will not respond to any of these interventions even after years of treatment
44 (Schlaepfer *et al.* 2013). For such completely treatment-refractory patients, neurosurgical
45 approaches can be considered. With such invasive approaches, which entail a lesion or implantation
46 of a device without previous demonstration of underlying brain pathology, careful evaluation of
47 risk/benefit ratios, patients’ consenting capacity, ethical aspects and national legal regulation are
48 paramount (Nuttin *et al.* 2014).

49

50 Over the last decade deep brain stimulation (DBS), first developed for pain, later mainly for
51 movement disorders and then for OCD, has emerged as a possible invasive treatment for depression

52 (Mayberg *et al.* 2005). The main DBS target sites for treating psychiatric disorders have been in the
53 anterior limb of the internal capsule, nucleus accumbens, subgenual cingulate gyrus and the medial
54 forebrain bundle (MFB) (Schlaepfer *et al.* 2013). Most studies of DBS for depression have reported
55 responder rates between 50-60% and remission rates around 35%. However, lack of control
56 conditions in the studies published so far, limited follow-up and a number of surgical and psychiatric
57 side effects need to be taken into consideration when evaluating the clinical scope of this method
58 (Schlaepfer *et al.* 2014; Kocabicak *et al.* 2015).

59

60 The other surgical approach is based on stereotactic lesions to key components of the cortical-
61 subcortical networks. Stereotactic lesions of the cingulum bundle (cingulotomy) and anterior limb of
62 the internal capsule (capsulotomy) have been performed on many hundreds of patients, mainly for
63 the indication of OCD (Greenberg *et al.* 2010). The main stereotactic procedure for depression has
64 been subcaudate tractotomy (Schoene-Bake *et al.* 2010). All these stereotactic procedures disrupt
65 connections between frontal and subcortical/limbic areas of the brain (Greenberg *et al.* 2010; Rauch,
66 1995). One common feature of all these approaches may be that they disrupt the MFB, which carries
67 the dopaminergic projections from the midbrain to the frontal lobe (Schoene-Bake *et al.* 2010;
68 Coenen *et al.* 2011).

69

70 The success rates (significant improvement) for inferior frontal (subcaudate and orbitomedial)
71 tractotomy in depression in older studies have varied between 34% and 72.7% (Göktepe *et al.* 1975;
72 Hodgkiss *et al.* 1995; Sachdev & Sachdev, 2005). A more recent study included 33 patients with
73 depression who had all undergone bilateral cingulotomy. About 75% of patients were classified as
74 partial or full responders. In addition, this study included formal clinical rating scales and found a
75 significant improvement on the BDI (Shields *et al.* 2008). In a cingulotomy case series of eight
76 depressed patients from Dundee, Scotland, two patients had responded and three remitted after
77 one year (Steele *et al.* 2008).

78

79 Capsulotomy for depression has been studied in fewer and smaller studies. After an initial positive
80 report from Sweden (Herner, 1961), there was a publication gap of half a century until a group in
81 Scotland (Christmas *et al.* 2011) published their series of 20 cases from 1992-1999. Their generally
82 positive clinical impression was supported by significant and long-term improvements on clinical
83 ratings of depression severity. However, not all measures were available for the same patients pre-
84 and post-operatively and thus had to be imputed. Another smaller study of 8 patients was published
85 by the Vancouver Limbic Surgery Group (Hurwitz *et al.* 2012) and their main finding was the
86 reduction or abolition of suicidal ideation experienced by all the patients. In the present study we
87 report on the other British case series of capsulotomy, covering 45 operations conducted in Cardiff,
88 Wales, between 1993 and 2008.

89

90 **METHODS:**

91 **Design and Patients:** We carried out a retrospective study on 45 patients who underwent bilateral
92 stereotactic anterior capsulotomy at the University Hospital of Wales (UHW), Cardiff from 1993-
93 2008 for TRD. This surgery is regulated under the Mental Health Act, 1983, which ensures that all
94 other appropriate treatment has been exhausted. All patients had received adequate periods of
95 treatment with a tricyclic antidepressant, an SSRI, a monoamine oxidase inhibitor, augmentation
96 strategies and ECT (except for 2 patients) with no or insufficient benefit. Patients were referred by
97 psychiatrists across the UK and assessed by the psychiatrist and neurosurgeon on the team and if
98 suitable referred to the Mental Health Act Commission (MHAC), as required by UK law (Mental
99 Health Act 1983, Section 57). Once assessed and approved by the MHAC panel (comprising a
100 psychiatrist and two non-medical members who reviewed all the case notes and conferred with the
101 referring consultant and with two other professionals involved with the case, and interviewed the
102 patient, before confirming that the surgery was appropriate, and consent was freely given and fully
103 informed) patients gave their written consent for the surgery.

104 Patients were discharged back to the care of the referring psychiatrist 1-2 weeks after surgery and
105 followed up clinically at one, three, six months and one year where possible and some (9 patients)
106 up to 6 years for clinical assessment. Psychometric assessment was carried out in most cases
107 between 6 and 12 months after surgery.

108 Here we report on the audit and clinical follow-up of this capsulotomy programme. Because of the
109 nature of the evaluation, the local Research and Development Office confirmed that this study was
110 exempt from ethical approval.

111

112 **Staging of treatment resistant depression:**

113 All patients who underwent surgery were diagnosed as treatment-resistant by the clinical team. For
114 this study we applied the Maudsley staging method which was used to determine the level of
115 treatment resistance. This method takes into consideration the duration of the presenting
116 depressive episode, symptom severity and treatment failures (Table 1).

117

118 **Surgical procedure:**

119 All patients were operated at the UHW by neurosurgeon BAS. Under general anaesthesia and with a
120 Leksell stereotactic frame applied, computerised tomographic (CT) guidance located the targets in
121 the anterior limbs of the internal capsules. Anatomical variation/asymmetry required bespoke
122 coordinates. These were based on the foramen of Monro – posterior commissure (FMPC) plane. Via
123 twist-drill holes, a stack of three (two in the first four cases) radiofrequency-generated
124 thermocoagulative lesions was made bilaterally at a single operation. Electrode tip 4mm x 1.6mm;
125 each lesion 75 degrees C (first 12 cases) or 80 degrees C (later cases) for 60 seconds (40 seconds in
126 the first seven cases). The 12mm column of targets was centred on the middle third (in the axial
127 plane) of the anterior limb of the internal capsule. The depth was increased during the series: in the
128 later cases the deepest target was 12mm below FMPC, 5mm deeper than in the early cases. This

129 would have been approximately 4 to 7mm below the anterior commissure (AC) level (the relation to
130 AC was not specifically recorded).

131 *Second Operations:*

132 Eleven of the 45 patients (of whom six are included in the psychometric analysis group; see
133 Statistical Analysis) had a second operation. All of them had initially experienced post-operative
134 improvement in their depression but this was lost, typically after approximately six to eight weeks.
135 This may reflect the effects of perilesional oedema and neuropraxia and their subsequent resolution.
136 In these 11 cases magnetic resonance (MR) scanning at six months post-operatively indicated one or
137 more lesions, on one or both sides, to be significantly smaller than the others or even not visible,
138 emphasised by any left-right asymmetry. These lesions were then enlarged at a second operation
139 after obtaining MHAC approval.

140

141 **Clinical imaging:**

142 All patients underwent CT scanning approximately one week post-operatively for an initial
143 assessment of lesion position, reactive oedema and any haemorrhage. Clinical MRI (T1 and T2
144 sequences) was performed at six months follow-up (Fig. 1).

145

146 **Clinical and Cognitive Measures:**

147 Pre- and post-surgical data were available on the BDI, Montgomery Asberg Depression Rating Scale
148 (MADRS) and Beck Anxiety Inventory (BAI) for subgroups of patients (see Table 2). A
149 neuropsychological battery of tests was also administered before and after surgery for some
150 patients. Measures used were the Wechsler Abbreviated Scale of Intelligence (WASI), Adult Memory
151 and Information Processing Battery, test of verbal fluency and tests of attention and concentration.
152 With a sample size of N=17 (which is our largest sample for complete cognitive data: verbal fluency

153 category) we had 80% power to detect medium effects on cognitive functioning (estimated required
154 effect size for one-tailed t-test: 0.53). (See Supplementary material Table 1S for all available data on
155 the clinical and cognitive measures).

156

157 **Statistical Analysis:**

158 Of the 45 operated patients demographic details, basic clinical information (Table 1) and adverse
159 outcomes are reported for all while psychometric measures are reported for 30 patients, as no
160 psychometric files were available for the remaining (early) cases.

161

162 The time of post-surgery psychometric follow-up varied for the measures. Follow-up MADRS
163 evaluations were performed between from one year and 4 years after surgery (except for 3 patients
164 who had follow-up of 3-6 months). Post-surgery BDI scores were from 3-6 months for half of the
165 patients and > 6 months follow-up for the other half of the patients. Follow-up of the other cognitive
166 measures varied from 3 months to >1 year.

167 For patients who had undergone a second operation where BDI pre and post-surgery scores were
168 available (four patients) the later scores were used in the analysis.

169 The outcome measures were analysed using the SPSS statistical package (IBM SPSS Statistics Version
170 20). For all measures we computed % change from pre to post surgery and confidence intervals
171 (Table 2). We also carried out a paired samples t-test on the outcome measures to determine any
172 statistically significant change in the group as a consequence of surgery.

173

174 **RESULTS:**

175 The Maudsley treatment resistant staging shows that all patients were categorised as having
176 moderately to severely treatment-resistant depression (Table 1). It is likely that our retrospective
177 staging process underestimated the severity of treatment resistance because information on
178 duration of current episode and medication treatment was incomplete for the patients classified as
179 moderately treatment resistant.

180 We compared the duration of illness and age at time of surgery between the patients with and
181 without psychometric measures using an independent samples t test. There was no difference in
182 the duration of illness ($t(43) = -.94$; $p = .35$) although those without psychometric measures were
183 older at the time of surgery ($t(43) = -2.03$; $p = .05$). As shown in Table 1, the groups with and without
184 psychometric data did not differ on any relevant parameter. For example, a Chi-Square test for
185 severity of treatment refractoriness yields $\chi^2(1) = .207$, $p = .65$ and thus no significant group
186 difference.

187

188 Even for the thirty patients for whom we had the psychometric files, data are in some cases
189 incomplete. This was due to difficulties in motivating them to attend to the full battery of tests.
190 Patients often requested testing to be terminated resulting in incomplete acquisition of data. Table 2
191 gives a summary of the psychometric analysis.

192 *Clinical outcomes:*

193 Pre and post-operative BDI scores were available for 24 patients. These showed an improvement by
194 -21.20 points (95% confidence interval -28.37 to -14.03) which represents a -52% change. A paired
195 samples t-test (2 tailed) showed a statistically significant difference between pre and post-surgery
196 BDI scores ($t(23) = -6.12$, $p = .00$).

197 Based on the BDI scores, 10 improved over 75%, 3 improved between 51 and 75%, 5 improved
198 between 26 and 50%, 3 improved by 25% or less. Three patients were worse than before surgery, by
199 3%, 14% and 38%.

200

201 This subgroup of 24 patients incorporated a stepwise increase in lesion depth. Initially, one lesion
202 was placed 5mm above the FM-PC plane and two deep to it. However, over time the lesions were
203 placed more deeply; in the later cases the highest was on the FM-PC plane, one 6mm below and one
204 12mm below. Of the last 10 patients (those with the deepest lesion sites), improvement by more
205 than 75% was seen after one operation in six; in the first 10 (those with the highest lesion sites) this
206 occurred in one after one operation, and subsequently in two more following a second operation.
207 We regard this as anecdotal evidence for an effect of lesion depth although our data do not allow for
208 a more formal investigation of a relationship between lesion depth and clinical improvement.

209 The BAI, available pre- and post-surgery for 13 patients, showed an improvement of 49% which was
210 significant ($t(12) = -3.27, p = .007$) (Table 2).

211 *Neuropsychological outcomes:*

212 Measures of executive functions, memory, concentration and attention showed no significant
213 change after surgery except for a small decline of digit span but very few patients (N= 5) were
214 included in the digit span analysis (Table 2).

215 *Adverse events (Table 3):*

216 One, chronically anorectic, patient died from pneumonia within a month of surgery. No motor or
217 sensory deficits occurred. One patient had transient focal seizures but one with medically-controlled
218 epilepsy had no seizures after either of his two operations. Another exhibited mildly increased
219 muscle tone and “cogwheeling” in both upper limbs for several months, which did not recur after a

220 second operation 16 months later and was not related to antipsychotic medication. Some patients
221 showed transient and mild confusion, transient incontinence of urine, fatigue and weight gain
222 (similar to the Dundee series (Christmas *et al.* 2011)). Data beyond 12 months are incomplete.

223 *Phone interviews:*

224 Psychiatrist DL conducted phone interviews with six patients who responded to letters from the
225 neurosurgeon inviting them for follow-up interviews in 2013. All had surgery for unipolar depression
226 except one (unipolar + comorbidity). These covered patients' experience between 5 and 15 years
227 post-surgery. This group reported a generally positive experience. Their mood symptoms had
228 improved considerably, and they had required many fewer hospital admissions than before the
229 operation, if any. Most of them did not need further ECT, although all of them continued to take
230 antidepressant medication. Memory problems and fatigue were reported as important side effects
231 (Table 4).

232

233 **DISCUSSION:**

234 The clinical outcome data from the capsulotomy series show considerable improvement of
235 depression and anxiety symptoms in this group of patients with otherwise treatment-refractory
236 depression. We found an improvement of 20 points on the BDI, which is similar to, or even larger
237 than, the effects commonly observed for ECT (Feliu *et al.* 2008) which is regarded to be the most
238 effective antidepressant treatment. It is thus remarkable that we found these antidepressant
239 benefits from capsulotomy in the present sample of patients who had been refractory to ECT.
240 Importantly, anxiety symptoms improved to a similar extent. Anecdotally, increasing lesion depth
241 improved the outcomes.

242 The profile of intra- and post-operative side effects was relatively favourable. There were no surgical
243 deaths and no motor or sensory deficits. One patient had focal seizures transiently, controlled with

244 medication. This incidence of seizures was similar to that reported after implantation of DBS
245 electrodes (Pouratian *et al.* 2011). One patient experienced transient extrapyramidal features. The
246 only infection, in a patient with diabetes, was superficial. Transient post-operative confusion and
247 urinary incontinence were relatively common. We did not detect deterioration in executive
248 functions, attention and concentration or memory functions on formal psychometric testing, but
249 cannot rule out changes in other cognitive domains (Dalglish *et al.* 2004). Some patients reported
250 fatigue, memory problems and lack of motivation, which had also been commonly reported
251 problems in previous studies of psychiatric surgery. Although we did not have formal long-term
252 follow-up data, the relatively high rate of memory complaints at the follow-up phone interviews
253 suggests that cognitive deficits may develop late.

254 Anhedonia, the core symptom of inability to experience pleasure, may be linked to a dysregulation
255 of networks of the reward system including the MFB and the anterior thalamic radiation (ATR). Both
256 these pathways are likely to be affected by anterior capsulotomy (Coenen *et al.* 2011; Bracht *et al.*
257 2014). The MFB is traditionally considered as the major “reward pathway” and the adjacent ATR may
258 mediate the experience of “grief” (Coenen *et al.* 2011). There is also some evidence for altered
259 structural connectivity of the MFB (Bracht *et al.* 2014) and ATR (Henderson *et al.* 2013) in
260 depression. DBS targeting the MFB led to remarkable clinical improvements in treatment-refractory
261 patients with major depressive disorder (Schlaepfer *et al.* 2013). Clinical improvement of patients
262 with depression following surgical interventions affecting these pathways may therefore be an effect
263 of rebalancing activation between the reward and grief system (Schlaepfer *et al.* 2013).

264 Diffusion Tensor Imaging (DTI)-based fibre-tracking enables the *in vivo* reconstruction of connection
265 pathways of the human brain (Catani *et al.* 2002) and may therefore be used for preoperative
266 planning and postoperative evaluation of putatively dissected pathways (Schlaepfer *et al.* 2013). In
267 three patients of our data set pre- and postoperative DTI data were available. We demonstrate and

268 discuss the potential use of DTI-data for future operations in a separate supplementary material (see
269 supplementary material).

270

271 Although patients with depression who do not respond to any non-invasive treatment continue to
272 pose a considerable clinical challenge, the number of patients undergoing surgery for depression
273 worldwide is at present very low. Cost and local availability of the procedures, evaluation of
274 risk/benefit ratios, lack of knowledge about this treatment modality for severely refractory patients
275 and fear of a potentially irreversible intervention are likely to contribute to this relatively low
276 uptake. However, the recent development of several DBS procedures for depression and other
277 mental disorders is likely to boost the interest in psychiatric surgery amongst patients and clinicians.
278 The published evidence base for DBS (Delaloye *et al.* 2014) and stereotactic lesion surgery for
279 depression is broadly similar –clinical improvements in uncontrolled studies with an acceptable side
280 effect profile, but with little supporting evidence from randomized controlled studies. The failure of
281 a recent DBS trial (Dougherty *et al.* 2015) to demonstrate superiority over sham stimulation in
282 depression may further rekindle interest in the results of ablative surgery.

283 The present study contributes a well-documented patient sample for the evaluation of adverse
284 events of psychiatric surgery and suggests that capsulotomy can be effective in the long term for
285 patients with otherwise refractory depression.

286

287 **Supplementary material:**

288 The supplementary material for this article can be found at
289 <https://doi.org/10.1017/S0033291716003159>.

290

291 **Acknowledgements:**

292 The authors were funded by Cardiff & Vale University Health Board, Cardiff University, and grants
 293 from the Wales Office of Research and Development (WORD) (Grant number SG02/012) and the
 294 Swiss National Science Foundation (SNF) (Grant number PBBEP3_144797). The funders had no
 295 involvement in the study.

296
 297 **Declaration of interest:**

298 None.

299

300 **REFERENCES:**

- 301 1 **Bracht T, Horn H, Strik W, Federspiel A, Schnell S, Hofle O, Stegmayer K, Wiest R, Dierks T,**
 302 **Muller TJ, Walther S** (2014): White matter microstructure alterations of the medial
 303 forebrain bundle in melancholic depression. *Journal of Affective Disorders* **155**, 186–93.
- 304 2 **Carvalho AF, Berk M, Hyphantis TN, McIntyre RS** (2014): The Integrative Management of
 305 Treatment-Resistant Depression: A Comprehensive Review and Perspectives. *Psychotherapy*
 306 *and Psychosomatics* **83**, 70-88.
- 307 3 **Catani M, Howard RJ, Pajevic S, Jones DK** (2002): Virtual in vivo interactive dissection of
 308 white matter fasciculi in the human brain. *NeuroImage* **17**, 77–94.
- 309 4 **Christmas D, Eljamel MS, Butler S, Hazari H, MacVicar R, Steele JD, Livingstone A,**
 310 **Matthews K** (2011): Long term outcome of thermal anterior capsulotomy for chronic,
 311 treatment refractory depression. *Journal of Neurology, Neurosurgery & Psychiatry* **82**, 594–
 312 600.
- 313 5 **Coenen VA, Schlaepfer TE, Maedler B, Panksepp J** (2011): Cross-species affective functions
 314 of the medial forebrain bundle-implications for the treatment of affective pain and
 315 depression in humans. *Neuroscience and Biobehavioural Reviews* **35**, 1971–81.

- 316 6 **Dagleish T, Yiend J, Bramham J, Teasdale JD, Ogilvie AD, Malhi G, Howard R** (2004):
317 Neuropsychological processing associated with recovery from depression after stereotactic
318 subcaudate tractotomy. *American Journal of Psychiatry* **161**, 1913-1916.
- 319 7 **Delaloye S, Holtzheimer PE** (2014): Deep brain stimulation in the treatment of depression.
320 *Dialogues in Clinical Neuroscience* **16**, 83–91.
- 321 8 **Dougherty DD, Rezai AR, Carpenter LL, Howland RH, Bhati MT, O'Reardon JP, Eskandar EN,**
322 **Baltuch GH, Machado AD, Kondziolka D, Cusin C, Evans KC, Price LH, Jacobs K, Pandya M,**
323 **Denko T, Tyrka AR, Brelje T, Deckersbach T, Kubu C, Malone DA** (2015): A Randomized
324 Sham-Controlled Trial of Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for
325 Chronic Treatment-Resistant Depression. *Biological Psychiatry* **78**, 240–248.
- 326 9 **El-Hage W, Leman S, Camus V, Belzung C** (2013): Mechanisms of antidepressant resistance.
327 *Frontiers in Pharmacology* **4:146**, 1-23.
- 328 10 **Feliu M, Edwards CL, Sudhakar S, McDougald C, Raynor R, Johnson S, Byrd G, Whitfield K,**
329 **Jonassaint C, Romero H, Edwards L, Wellington C, Hill BK, Sollers J, Logue PE** (2008):
330 Neuropsychological effects and attitudes in patients following electroconvulsive therapy.
331 *Neuropsychiatric Disease and Treatment* **4**, 613–17.
- 332 11 **Göktepe EO, Young LB, Bridges PK** (1975): A further review of the results of stereotactic
333 subcaudate tractotomy. *British Journal of Psychiatry* **126**, 270–80.
- 334 12 **Greenberg BD, Rauch SL, Haber SN** (2010): Invasive Circuitry-Based Neurotherapeutics:
335 Stereotactic Ablation and Deep Brain Stimulation for OCD. *Neuropsychopharmacology*
336 *Reviews* **35**, 317–36.
- 337 13 **Henderson SE, Johnson AR, Vallejo AI, Katz I, Wong E, Gabbay E** (2013): A preliminary study
338 of white matter in adolescent depression: relationships with illness severity, anhedonia, and
339 irritability. *Frontiers in Psychiatry* **4**, Article 152.
- 340 14 **Herner T** (1961): Treatment of Mental Disorders with Frontal Stereotaxic Thermo-Lesions. A
341 Follow-up of 116 cases. *Acta Psychiatrica Scandinavica* **36** (Suppl 158).

- 342 15 **Hodgkiss AD, Malizia AL, Bartlett JR, Bridges PK** (1995): Outcome after the psychosurgical
343 operation of stereotactic subcaudate tractotomy, 1979-1991. *Journal of Neuropsychiatry*
344 *and Clinical Neurosciences* **7**, 230–34.
- 345 16 **Hurwitz TA, Honey CR, Allen J, Gosselin C, Hewko R, Martzke J, Bogod N, Taylor P** (2012):
346 Bilateral anterior capsulotomy for intractable depression. *Journal of Neuropsychiatry and*
347 *Clinical Neurosciences* **24**, 176-182.
- 348 17 **Kocabicak E, Temel Y, Hollig A, Falkenburger B, Tan SKH** (2015): Current perspectives on
349 deep brain stimulation for severe neurological and psychiatric disorders. *Neuropsychiatric*
350 *Disease and Treatment* **11**, 1051-66.
- 351 18 **Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwalb JM,**
352 **Kennedy SH** (2005): Deep brain stimulation for treatment-resistant depression. *Neuron* **45**,
353 651-660.
- 354 19 **Nuttin B, Wu H, Mayberg H, Hariz M, Gabriels L, Galert T, Merkel R, Kubu C, Vilela-Filho O,**
355 **Matthews K, Taira T, Lozano AM, Schechtmann G, Doshi P, Broggi G, Regis J, Alkhani A, Sun**
356 **B, Eljamel S, Schulder M, Kaplitt M, Eskandar E, Rezai A, Krauss JK, Hilven P, Schuurman R,**
357 **Ruiz P, Chang JW, Cosyns P, Lipsman N, Voges J, Cosgrove R, Li Y, Schlaepfer T** (2014):
358 Consensus on guidelines for stereotactic neurosurgery for psychiatric disorders. *Journal of*
359 *Neurology, Neurosurgery and Psychiatry* **0**, 1–6.
- 360 20 **Pouratian N, Reames DL, Frysinger R, Elias WJ** (2011) : Comprehensive analysis of risk
361 factors for seizures after deep brain stimulation surgery. *Journal of Neurosurgery* **115**, 310–
362 15.
- 363 21 **Rakofsky JJ, Holtzheimer PE, Nemeroff CB** (2009): Emerging targets for antidepressant
364 therapies. *Current Opinion in Chemical Biology* **13**, 291-302.
- 365 22 **Rauch SL** (1995): Psychosurgery. *Neurosurgery Clinics of North America* **6**, 167–76.
- 366 23 **Sachdev PS, Sachdev J** (2005): Long-term outcome of neurosurgery for the treatment of
367 resistant depression. *Journal of Neuropsychiatry and Clinical Neurosciences* **17**, 478–85.

- 368 24 **Schlaepfer TE, Bewernick BH, Kayser S, Madler B, Coenen VA** (2013): Rapid Effects of Deep
369 Brain Stimulation for Treatment-Resistant Major Depression. *Biological Psychiatry* **73**, 1204-
370 12.
- 371 25 **Schlaepfer TE, Bewernick BH, Kayser S, Hurlmann R, Coenen VA** (2014): Deep Brain
372 Stimulation of the Human Reward System for Major Depression-Rationale, Outcomes and
373 Outlook. *Neuropsychopharmacology* **39**, 1303–14.
- 374 26 **Schoene-Bake JC, Parpaley Y, Weber B, Panksepp J, Hurwitz TA, Coenen VA** (2010).
375 Tractographic analysis of historical lesion surgery for depression. *Neuropsychopharmacology*
376 **35**, 2553–63.
- 377 27 **Shields DC, Asaad W, Eskandar EN, Jain FA, Cosgrove GR, Flaherty AW, Cassem EH, Price**
378 **BH, Rauch SL, Dougherty DD** (2008): Prospective assessment of stereotactic ablative surgery
379 for intractable major depression. *Biological Psychiatry* **64**, 449–54.
- 380 28 **Steele JD, Christmas D, Eljamel MS, Matthews K** (2008): Anterior cingulotomy for major
381 depression: clinical outcome and relationship to lesion characteristics. *Biological Psychiatry*
382 **63**, 670–77.
- 383 29 **UK ECT Review Group** (2003): Efficacy and safety of electroconvulsive therapy in depressive
384 disorders: a systematic review and meta-analysis. *Lancet* **361**, 799-808.

385

386

387

388

389

390

391 **Tables:**392 **Table 1:** Demographics and Treatment resistance according to the Maudsley staging method: N=45

Demographics	Patients with Psychometric data				Patients without Psychometric data		
	Unipolar	Unipolar + Comorbidity	Bipolar	Bipolar + Comorbidity	Unipolar	Unipolar + Comorbidity	Bipolar
Number of Patients	16	11	2	1	6	4	5
Male	1	5	1	1	3	1	3
Female	15	6	1	0	3	3	2
Age at time of surgery in years							
Median	45.50	41	46.50	34	55.50	35.50	69
Interquartile Range	13.50	14	18.50	0	13.25	9.75	20.50
Last follow-up after surgery in months							
Median	30	24	36	72	66	45	39
Interquartile Range	57	52	24	0	73.25	160.50	46
Total duration of illness in years							
Median	20	20	16.75	10	16.50	17.50	35
Interquartile Range	15.50	11	10.25	0	26	17	31
History regarding Suicide							
Attempts	13	5	1	1	3	2	2
Ideation	3	2	0	0	0	1	2
None	0	0	0	0	0	0	0
Not known	0	3	1	0	3	1	1
Treatment resistance: Maudsley staging							
Symptom severity:							
Severe without psychosis	13	10	2	1	6	4	4
Severe with psychosis	3	1	0	0	0	0	1
Duration of current episode:							
Acute	1	0	1	0	0	0	0
Sub-acute	5	3	0	0	2	2	2

Chronic	10	5	0	1	4	2	2
Not known	0	3	1	0	0	0	1
Treatment failures:							
Antidepressants (No. of medications):							
3-4	10	8	2	0	4	2	3
5-6	6	2	0	1	2	0	1
7-10	0	0	0	0	0	1	0
>10	0	1	0	0	0	1	1
Augmentation: Used	16	11	2	1	6	4	5
Electroconvulsive therapy (ECT): Used	16	9	2	1	6	4	5
Known Psychological therapies	14	7	1	1	1	1	0
Severity category::							
Moderate	4	4	2	0	1	1	2
Severe	12	7	0	1	5	3	3

393 **Footnote: All patients had had psychiatric hospital admissions but details were not available in all cases.**

394

395

396

397

398

399

400

401

402

403 **Table 2:** Pre and Post-surgery clinical and cognitive measures:

Measures	N ^a	Pre-surgery Mean	± SE	Treatment change (Post - Pre surgery Mean	± SE	95% CI	% change ^h	t	P (2-tailed)
Clinical Rating Scales:									
BDI ^b	24	41.17	2.0	-21.20	3.46	-28.37 to -14.03	-52	-6.12	.000
BAI ^d	13	27.38	3.04	-13.61	4.15	-22.66 to -4.56	-49	-3.27	.007
Cognitive Measures:									
General intelligence (WASI)^e:									
Verbal IQ	11	100.36	5.88						
Performance IQ	11	96.82	5.59						
Full Scale IQ	9	96.11	6.50						
Executive functions:									
Verbal fluency	17	33.76	3.64	-3.35	2.53	-8.73 to 2.02	-10	-1.32	.20
Similarities	5	8.40	1.74	1.40	2.58	-5.76 to 8.56	17	.54	.61
Attention and concentration:									
Speed processing	9	36.67	2.42	6.11	4.64	-4.59 to 16.81	17	1.31	.22
Information processing	12	45.83	4.98	2.58	3.21	-4.49 to 9.66	6	.80	.43
Digit span (scaled scores)	5	8	1.81	1.20	.37	.16 to 2.23	15	3.20	.03
Digit symbol (scaled scores)	6	5.83	.40	.50	.50	-.78 to 1.78	9	1.0	.36
Memory: Immediate and delayed:									
List learning	12	41.83	3.34	-3.50	2.48	-8.96 to 1.96	-8	-1.40	.18
Story IR ^f	19	27.47	2.14	1.10	3.04	-5.28 to 7.49	4	.36	.72

Story DR ^g	19	21.53	2.32	2.0	3.06	-4.44 to 8.44	9	.65	.52
Figure IR	18	58.61	6.33	4.72	4.68	-5.16 to 14.60	8	1.00	.32
Figure DR	18	54.39	6.34	.50	6.33	-12.86 to 13.86	1	.07	.93

404

405 **Footnote:** a) N = number of patients; b) BDI = Beck Depression Inventory; d) BAI = Beck Anxiety Inventory; e)

406 WASI = Wechsler Abbreviated Scale of Intelligence; f) IR= Immediate Recall; g) DR = Delayed Recall.

407 h) A negative score on the clinical scales indicates an improvement and for the cognitive measures a positive

408 score indicates an improvement.

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423 **Table 3:** Frequency and duration of adverse effects: N = 45

Adverse Events	Patients with Psychometric data				Patients without Psychometric data		Total
	Unipolar	Unipolar + Comorbidity	Bipolar	Bipolar + Comorbidity	Unipolar	Unipolar + Comorbidity	
Seizures:							1
Up to 1 week	0						
Up to 1 year	1						
>1 year	0						
Extrapyramidal S/E:							1
Up to 1 week	0						
Up to 1 year	1						
>1 year	0						
Infection^a:							1
Up to 1 week					1		
Up to 1 year					0		
>1 year					0		
Urinary incontinence:							24
Up to 1 week	9	5	1	1	5	2	
Up to 1 year	1	0	0	0	0	0	
>1 year	0	0	0	0	0	0	
Confusion/disorientation:							24
Up to 1 week	7	8	2	1	5	1	
Up to 1 year	0	0	0	0	0	0	
>1 year	0	0	0	0	0	0	
Tiredness/Fatigue:							14
Up to 1 week	1	0	0		2	1	
Up to 1 year	4	2	2		0	1	
>1 year	0	1	0		0	0	
Short term memory problems:							10
Up to 1 week	1	0		0	0	0	

Up to 1 year	3	1		1	0	0	
>1 year	2	0		0	1	1	
Weight gain:							3
Up to 1 week	0	0			1		
Up to 1 year	1	0			0		
>1 year	0	1			0		
Personality change:							2
Up to 1 week	0						
Up to 1 year	0						
>1 year	2						
Lack of motivation:							6
Up to 1 week	0					1	
Up to 1 year	1					0	
>1 year	4					0	
Impaired attention & concentration:							4
Up to 1 week	0	0					
Up to 1 year	0	1					
>1 year	3	0					

424

425 **Footnote:** a) A superficial pin-site infection occurred in a type-1 diabetic.

426 Data beyond 1 year are incomplete

427

428

429

430

431

432


433

434 **Table 4:** Interviewed patients:

Age at interview/ year of surgery	Pre-OP history	Outcome	Antidepressant Medication	Side effects
63/ 2004	10 years	"I think it was wonderful" – whole life has improved – she became a "different person" as if waking from "deep sleep"	Yes	Memory problems
63/ 2003	35 years	"Transformed my life" – does not feel depressed any longer – but "would not recommend it" because of side effects	Yes	Weight gain, fatigue, lost ability to visualise places
53/ 2001	12 years	"Quite pleased" but has not stopped depression	Yes	Memory problems
62/ 2000	3 years	Depressive episodes have become much less frequent, "highs" more frequent	Mood stabilisers	Memory problems
67/ 2008	23 years	Depression and nihilistic thoughts went immediately	Yes	Memory problems, lack of motivation
59/ 1998	5.5 years	Has made a difference, although benefits becoming smaller as time moves on – would have the procedure again	Yes	None

435

436

437 **Figure 1:** T2 weighted MRI coronal scans: left: unoperated; right: 6 months post-surgery.

438

439

440 **Supplementary Material:**441 **Table 1S:** The pre- and post-surgical clinical and cognitive psychometric scores which were available for 30

442 patients. Subjects not in surgical date order.

Measures	Subjects														
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
BDI-Pre	40	15 (HADS)	17 (HADS)	49	42	59	23	32	38	42	49		51	43	56
BDI-Post	24	13 (HADS)	4 (HADS)	14	18	9	3	6	39	29	9	39	5	1	53
MADRS-Pre									22						
MADRS-Post		24			14	12	5	9	4					18	40
BAI-Pre		15 (HADS)	13 (HADS)	30	26	14	25	35	25	17	28				
BAI-Post		16 (HADS)	15 (HADS)	29	17	1	2	4	26	27	15				23
V-IQ	118		97				126	91		95			129	76	
P-IQ	89		91				133	108		108			84	63	
FS-IQ			94				133	90		102				69	
VF-Pre		37	58	21	23	13	57	41	36	24	34				
VF-Post		24	42	12	28	23	56	35	34	29	15	28	42		21
S-Pre	13	7		10		6	15	11		9			15	5	
S-Post	9	6				17						11			8
SP-Pre				48	5	30	42		33	41	31				
SP-Post				43		60	58	50	28	29	30	36	47	35	41
IP-Pre				50	29	35	79	44	28	38	23				
IP-Post				60	30	54	101	46	30	40	10	65	60	33	34
DS-Pre	12	5	7	6		10							6	6	
DS-Post		5	9			11						13			8
DSy-Pre	6	6	7						5					2	
DSy-Post	5	6	9												
LL-Pre				39		29	56	49	36	38				20	
LL-Post				30	43	35	40	35	34	40			40	30	37
S_IR-Pre	36	29	28	32	5	10	35	24	18	24	26		30	34	
S_IR-Post	39	19	32	14	38	30	22	44	26	25	10	39	23	29	35
S_DR-Pre	31	21	24	22	3	3	35	16	16	16	15		21	23	
S_DR-Post	36	6	30	0	37	20	25	38	24	21	2	36	25	21	26
F_IR-Pre	49	75	38	67	3	55	90	75	41	96	26		51	56	
F_IR-Post	33	90	53	63	70	65	97	84	34	92	21	61	80	38	48
F_DR-Pre	59	43	38	63	0	60	90	59	42	93	25		36	38	
F_DR-Post	33	38	44	0	70	61	97	68	34	95	18	50	81	33	56
Measures	Subjects														
	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30
BDI-Pre	42		26	32	56	37	37	25	47	29	52	34	30		42
BDI-Post	23	40	36	24	54	42	25		5	5	25	25	1		4
MADRS-Pre		40										25			23
MADRS-Post	11	21	21	11					13		22			12	6
BAI-Pre	50		35			41		0	40	12					18
BAI-Post	2		23	36	17	18	25			4					11
V-IQ	82					107				111			72		
P-IQ	102					97				110			80		
FS-IQ	88					102				113			74		
VF-Pre	19		11	39		45		17		51			18		47
VF-Post	22		12	36	24	21	38			44		23	33		51
S-Pre	9		4			12		6	12	38			4		
S-Post		11				11							6		
SP-Pre							40	54		25					40
SP-Post							44			47					46
IP-Pre	61						65	44		38					60
IP-Post	50						53			45					62
DS-Pre	8		6			14		8					4		
DS-Post		13				15	6						6		
DSy-Pre	10		4			6		2					6		
DSy-Post			4			6	6						8		
LL-Pre	43		33					39		50	49				60
LL-Post	32		24							55	42				63

S_IR-Pre	20		25	44		36		17		36			32		42
S_IR-Post	21	39	18		10	25	24			41			40		47
S_DR-Pre	14		18			28		16		37			25		41
S_DR-Post	6	36	15	44	7	23	26			38			35		45
F_IR-Pre	95		18			53		97					84		83
F_IR-Post	94		27	75	30	46	59						67		85
F_DR-Pre	95		18			58		89					78		84
F_DR_Post	95		28	83	26	46	59						67		80

443

444 **Footnote: Footnote:** BDI = Beck Depression Inventory; HADS = Hospital anxiety and depression scale (these
445 scores were available for 2 patients and replace the BDI (HADS depression scale) and BAI (HADS anxiety scale)
446 where indicated); MADRS = Montgomery Asberg Depression Rating Scale; BAI = Beck Anxiety Inventory; I =
447 Imputed; V = Verbal; P = Performance; FS = Full Scale; VF = Verbal Fluency; S = Similarities; SP = Speed
448 Processing; IP = Information Processing; DS = Digit Span; DSy = Digit Symbol; LL = List Learning; S = Story; F =
449 Figure; IR= Immediate Recall; DR = Delayed Recall.

450

451 **Diffusion Tensor Imaging:**

452 **The potential use of DTI-based fibre tracking**

453 Diffusion Tensor Imaging (DTI)-based fibre-tracking enables the *in vivo* reconstruction of connection
454 pathways of the human brain (Catani *et al.* 2002). Previous research suggests that white matter
455 microstructure of the medial forebrain bundle (MFB) and the anterior thalamic radiation (ATR),
456 pathways that are likely to be interrupted during anterior capsulotomy, are altered in depression (Jia
457 *et al.* 2014; Bracht *et al.* 2014). Based on a recent review these changes are most pronounced in
458 MDD patients with severe/ treatment-resistant depression (Bracht *et al.* 2015). Thus the MFB and
459 ATR may be of particular relevance regarding the clinical effects of anterior capsulotomy. Pre-
460 operative DTI-based identification of target fibre tracts that may underlie depression
461 symptomatology may therefore potentially represent an important step forward in psychiatric
462 surgery. Furthermore, DTI fibre tracking may be used for evaluation of surgical outcome, and to link
463 side effects to the lesioning of specific pathways. In three patients pre- and postoperative DTI data
464 were available and analyzed.

465 **Methods:**466 *Diffusion Tensor Imaging (DTI):*

467 Data were acquired on a clinical GE Medical System 1.5 Tesla scanner with the following parameters:

468 24 diffusion encoding directions with a b-value of 1000 s/mm², 1B0 image without diffusion

469 weighting, 30 slices, voxel size 2x2x5 mm. Pre and post diffusion-MRI data were available for three

470 patients.

471 *Imaging Analysis:*

472 Data were pre-processed and analysed using the software package *ExploreDTI* (Leemans *et al.* 2009).

473 Regions of interest of connection pathways were chosen from the automated anatomical labelling

474 (AAL) atlas (Tzourio-Mazoyer *et al.* 2002), implemented in *ExploreDTI* (Leemans *et al.* 2009). We


475 hypothesized the thalamo-orbitofrontal cortex (OFC) connection pathway to be interrupted by the

476 operation. For reconstruction of this pathway the thalamus and Brodmann areas 10 and 11 were

477 chosen as seed regions. The thalamo-primary motor cortex (PMC) connection was reconstructed as a

478 comparison tract which we did not expect to be affected by the operation. These two connection

479 pathways were separately reconstructed for individual pre-surgical and post-surgical datasets.

480 **Results:**

481

482 **Figure 1S: Fibre connections between the thalamus and orbitofrontal cortex pre and post-surgery**
 483 **(left panel) and fibre connections between the thalamus and primary motor cortex pre and post-**
 484 **surgery (right panel). BDI clinical scores for the 3 patients: Row 1: Pre-42, Post-4, 90% change; Row**
 485 **2: Pre-42, Post-29, 31% change; Row 3: Pre-49, Post-9, 82% change.**

486

487 In all pre-surgery DTI scans both bilateral thalamo-OFC connection pathways travelling through the
488 anterior limb in the internal capsule and bilateral thalamo-PMC pathways running through the
489 cortico-spinal tract could be identified reliably.

490 In the post-operative DTI scans in one participant no fibres connecting thalamus and OFC could be
491 identified (row 1, Figure 1B). In two participants DTI-fibre-tracking revealed sparse unilateral
492 connection pathways between the OFC and the thalamus running through the external capsule (row
493 2 and row 3, Figure 1B). These fibres had not been reconstructed before the operation. Bilateral
494 thalamo-PMC connections remained unchanged in comparison to the pre-operative DTI scan.

495 ***Discussion***

496 At present diffusion MRI is the only available method for in vivo reconstruction of fibre pathways
497 and thus offers unique opportunities in psychiatric surgery and stimulation studies. Our DTI-fibre
498 tracking results support the assumption that pathways connecting the thalamus and OFC have been
499 successfully interrupted. DTI fibre tracking results of the thalamo-PMC comparison pathway
500 remained unchanged after the operation, indicating that the surgical intervention had no effect on
501 more posterior thalamo-cortical connections.

502 We suggest that DTI-fibre tracking will find more widespread use in future applications of psychiatric
503 surgery. It may be used to reconstruct pathways before the operation and serve as guidance to
504 specifically modulate pathways of interest; postoperative DTI-fibre tracking may validate surgery
505 outcome; follow-up studies could link the lesioning of specific pathways to treatment outcome and
506 side effects. This may contribute to the development of more specific and less invasive surgery,
507 potentially being associated with fewer side effects. DTI-based tractography has already informed
508 new protocols for DBS (Coenen *et al.* 2011) and is being used to localize stimulation targets
509 (Schlaepfer *et al.* 2013).

510

511 **References:**

512 **1 Bracht T, Horn H, Strik W, Federspiel A, Schnell S, Hofle O, Stegmayer K, Wiest R, Dierks T, Muller**

513 **TJ, Walther S** (2014): White matter microstructure alterations of the medial forebrain bundle in

514 melancholic depression. *Journal of Affective Disorders* **155**, 186–93.

515 **2 Bracht T, Linden DEJ, Keedwell P** (2015). A review of white matter microstructure alterations of

516 pathways of the reward circuit in depression. *Journal of Affective Disorders* **187**, 45–53.

517 **3 Catani M, Howard RJ, Pajevic S, Jones DK** (2002): Virtual in vivo interactive dissection of white

518 matter fasciculi in the human brain. *NeuroImage* **17**, 77–94.

519 **4 Coenen VA, Schlaepfer TE, Maedler B, Panksepp J** (2011): Cross-species affective functions of the

520 medial forebrain bundle-implications for the treatment of affective pain and depression in humans.

521 *Neuroscience and Biobehavioural Reviews* **35**, 1971–81.

522 **5 Jia Z, Wang Y, Huang X, Kuang W, Wu Q, Lui S, Sweeney JA, Gong Q** (2014) : Impaired

523 frontothalamic circuitry in suicidal patients with depression revealed by diffusion tensor imaging at

524 3.0 T. *Journal of Psychiatry and Neuroscience* **39**, 170–7.

525 **6 Leemans A, Jeurissen B, Sijbers J, Jones D** (2009) : ExploreDTI: a graphical toolbox for processing,

526 analyzing and visualizing diffusion MR data. *Proceedings of the International Society for Magnetic*

527 *Resonance in Medicine 17th Annual Meeting*; April 18-24, 2009; Honolulu, Hawaii, **3536**.

528 **7 Schlaepfer TE, Bewernick BH, Kayser S, Madler B, Coenen VA** (2013): Rapid Effects of Deep Brain

529 Stimulation for Treatment-Resistant Major Depression. *Biological Psychiatry* **73**, 1204-12.

530 **8 Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B,**

531 **Joliot M** (2002) : Automated anatomical labeling of activations in SPM using a macroscopic

532 anatomical parcellation of the MNI MRI single-subject brain. *NeuroImage* **15**, 273–89.

533